Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2023
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $150,000
- Purchase Price (Net Proceeds): $135,000
- Interest Rate: 10% per annum
- Maturity Date: December 8, 2024
- Use of Proceeds: General working capital
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt levels outside of this specific note.
Material Changes and Transaction Details
The Company entered into a Securities Purchase Agreement with an investor to issue a convertible promissory note. Material terms include:
- Conversion Terms: Convertible into common stock at the investor's option after six months. The conversion price is set at 60% of the lowest traded price of the common stock during the 15 trading days prior to conversion.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
- Prepayment Rights: The Company may prepay the note with a premium ranging from 115% to 140% of the face amount plus accrued interest, depending on the timing (within the first 180 days). No prepayment right exists after 180 days.
- Reserve Requirement: The Company must maintain an initial reserve of at least 500% of the number of potential conversion shares.
Guidance, Risks, and Contingencies
Events of Default: The note contains specific events of default that would make the note immediately due and payable, including:
- Failure to pay principal or interest when due.
- Failure to timely issue conversion shares.
- Failure to maintain the listing of common stock on at least one OTC market or equivalent exchange.
- Failure to comply with SEC reporting requirements.
- Insolvency, bankruptcy, or liquidation.
Regulatory Status: The note was issued pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the Company's current cash position to assess the ability to service the 10% interest and potential prepayment premiums.
- Confirm the Company's compliance with OTC market listing requirements to avoid triggering an event of default.
- Review the Company's authorized share count to ensure the 500% reserve requirement for conversion shares can be met.
- Monitor the trading price of the common stock, as the conversion price is tied to the lowest traded price over a 15-day period, which could lead to significant dilution.
- Check for any subsequent filings regarding the Company's ability to meet SEC reporting obligations.